EPYC Human Recombinant is produced in HEK293 cells as a single glycosylated polypeptide chain containing 309 amino acids (residues 20-322) with a C-terminal 6x His-tag. Key characteristics include:
Property | Specification |
---|---|
Molecular Mass | 35.5 kDa |
Purity | >95% (SDS-PAGE) |
Biological Activity | >60% adhesion support for Saos-2 cells |
Storage | 10% glycerol in PBS (pH 7.4) |
Stabilization | Requires 0.1% HSA/BSA for long-term storage |
This recombinant form retains functional properties, enabling studies on cell-matrix interactions and signaling pathways .
EPYC regulates extracellular matrix dynamics through:
Collagen Fibrillogenesis: Binds collagen fibrils to modulate tissue architecture .
Growth Factor Modulation: Interacts with TGF-β and BMPs to influence chondrogenesis and osteogenesis .
Cell Adhesion/Proliferation: Supports osteosarcoma cell adhesion via integrin-mediated pathways .
Dysregulation is linked to osteoarthritis, high myopia, and cancer progression .
Recent studies identify EPYC as an oncogenic driver in pancreatic cancer (PC):
Parameter | Result |
---|---|
Expression in PC Tumors | 3.8-fold increase vs. normal tissue |
Survival Correlation | High EPYC = 34% lower 5-year survival |
Pathway Activation | PI3K-AKT (p-AKT elevation) |
Functional Impact | Promotes proliferation, migration, and tumor growth in vitro/in vivo |
Knockdown of EPYC reduces PC cell viability by 40–60% (CCK8/EdU assays) .
Suppresses E-cadherin while upregulating Vimentin and PCNA, indicating epithelial-mesenchymal transition (EMT) promotion .
Subcutaneous xenograft models show 50% smaller tumors with EPYC silencing .
EPYC’s dual role as a biomarker and therapeutic target is under exploration:
Diagnostic Utility: Elevated serum EPYC levels correlate with advanced PC stages (AUC = 0.87 in ROC analysis) .
Therapeutic Strategies:
EPYC Human is utilized in:
Cell Adhesion Assays: Quantified via Saos-2 osteosarcoma cell adherence .
Matrix Remodeling Studies: Evaluated in 3D cartilage/organoid models .
High-Throughput Screening: For drug discovery targeting proteoglycan-driven cancers .
Ongoing research focuses on:
Epiphycan, SLRR3B, DSPG3, EPYC Dermatan sulfate proteoglycan 3, Proteoglycan-Lb, PG-Lb, Small chondroitin/dermatan sulfate proteoglycan, PGLB, epiphycan proteoglycan.
HEK293 Cells.
APTLESINYD SETYDATLED LDNLYNYENI PVDKVEIEIA TVMPSGNREL LTPPPQPEKA QEEEEEEEST PRLIDGSSPQ EPEFTGVLGP HTNEDFPTCL LCTCISTTVY CDDHELDAIP PLPKNTAYFY SRFNRIKKIN KNDFASLSDL KRIDLTSNLI SEIDEDAFRK LPQLRELVLR DNKIRQLPEL PTTLTFIDIS NNRLGRKGIK QEAFKDMYDL HHLYLTDNNL DHIPLPLPEN LRALHLQNNN ILEMHEDTFC NVKNLTYIRK ALEDIRLDGN PINLSKTPQA YMCLPRLPVG SLVHHHHHH.
The EPYC gene encodes Epiphycan, a small leucine-rich proteoglycan that plays a crucial role in cartilage extracellular matrix organization. Based on recent studies, EPYC is expressed during cartilage development and is particularly associated with articular cartilage phenotype . Notably, it appears to be down-regulated during the transition to hypertrophic chondrocytes, suggesting it maintains the pre-hypertrophic chondrocyte state in normal development.
Methodological approach: To investigate EPYC's role in skeletal development, researchers should employ a multi-faceted approach:
Gene expression analysis during different stages of chondrogenesis using qRT-PCR
Spatial localization studies using RNA in situ hybridization or immunohistochemistry
Functional studies using gene knockdown or overexpression in appropriate cell culture models
Correlation of EPYC expression with cartilage matrix production and quality
From available data, EPYC expression appears to be downregulated by T3 (triiodothyronine) treatment at day 69 of differentiation , suggesting hormonal regulation of its expression. This down-regulation occurs alongside other cartilage-specific genes including COL11A1, COL9A1, COL9A2, COL9A3, MATN1, LUM, COMP, and EDIL3 during the transition to hypertrophic chondrocytes.
Methodological approach:
Time-course experiments tracking EPYC expression during in vitro chondrocyte differentiation
Treatment studies with various hormones, growth factors, and cytokines to identify regulatory signals
Promoter analysis using reporter constructs to identify key regulatory elements
ChIP-seq analysis to identify transcription factors binding to the EPYC promoter region
Epigenetic profiling to identify DNA methylation or histone modification changes during differentiation
Based on current research, induced pluripotent stem cells (iPSCs) differentiated toward chondrogenic lineage represent a valuable model system for studying EPYC function . This model allows researchers to recapitulate endochondral bone formation in vitro.
Methodological approach:
3D pellet culture systems to promote chondrogenesis from iPSCs
Directed differentiation protocols that pass through developmental intermediates (primitive streak, paraxial mesoderm, somitic mesoderm, and sclerotome)
Manipulation of culture conditions to direct cells toward articular or growth plate cartilage phenotypes
Analysis of gene expression, histology, and functional assays to assess the impact of EPYC modulation
Comparison with primary chondrocyte cultures and tissue explants to validate findings
Recent research describes a method to direct iPSC-derived sclerotome to chondroprogenitors in 3D pellet culture, which can then be directed toward either articular chondrocytes or growth plate cartilage pathway . This system provides several advantages for studying EPYC function.
Methodological approach:
Generation of isogenic iPSC lines with EPYC mutations using CRISPR-Cas9 gene editing
Differentiation of modified and control iPSCs to compare phenotypic differences
Implementation of reporter systems to track EPYC expression in real-time
Co-culture experiments to investigate cell-cell interactions and paracrine signaling effects on EPYC expression
Application of mechanical stimulation or 3D bioprinting to create more physiologically relevant models
Effective methodologies include comprehensive transcriptomic profiling to identify gene expression signatures during key developmental stages.
Methodological approach:
Bulk RNA-seq analysis of differentiated cell populations at defined timepoints
Single-cell RNA-seq to capture heterogeneity within differentiating populations
Spatial transcriptomics to preserve positional information within 3D constructs
Proteomics analysis to verify translation of EPYC mRNA and post-translational modifications
Integration of multi-omics data to place EPYC within developmental regulatory networks
Data from literature:
Gene expression analysis shows EPYC is strongly expressed during early chondrogenesis but downregulated during hypertrophic differentiation in response to T3 treatment .
While specific correlations between EPYC mutations and skeletal disorders are not detailed in the current literature, the iPSC-derived model system "can be used to model genetic cartilage and bone disorders, and search for therapies" .
Methodological approach:
Whole exome/genome sequencing of patients with undiagnosed skeletal disorders
Variant filtering and prioritization focusing on cartilage-related genes including EPYC
Generation of patient-derived iPSCs containing naturally occurring EPYC mutations
Differentiation along chondrogenic lineage to observe phenotypic abnormalities
Gene correction experiments to establish causality
High-throughput drug screening to identify compounds that rescue mutant phenotypes
Commercial siRNA products targeting EPYC are available, such as "EPYC Human Pre-designed siRNA Set A" which contains designed siRNAs for the EPYC gene , suggesting siRNA technology is being used to study EPYC function.
Methodological approach to overcome challenges:
Optimization of transfection protocols specific for chondrocyte or chondroprogenitor cells
Testing different transfection reagents and conditions
Establishing electroporation parameters for high efficiency and low toxicity
Validation strategies:
qRT-PCR to verify mRNA knockdown efficiency
Western blotting or ELISA to confirm protein reduction
Functional assays to assess physiological impact
Control implementation:
Use of multiple siRNA sequences targeting different regions of EPYC
Inclusion of non-targeting control siRNAs
Rescue experiments with siRNA-resistant EPYC constructs
The research literature mentions EPYC alongside other key cartilage ECM molecules including collagens (COL2A1, COL11A1, COL9A1, etc.), aggrecan (ACAN), HAPLN1, and matrilins (MATN1, MATN3) .
Methodological approach:
Protein-protein interaction studies:
Co-immunoprecipitation followed by mass spectrometry
Proximity ligation assays in native cartilage tissue
Biolayer interferometry or surface plasmon resonance for binding kinetics
Structural analysis:
X-ray crystallography or cryo-EM of EPYC-ECM protein complexes
Molecular dynamics simulations to predict interaction domains
Functional interaction studies:
Coordinated gene knockdown experiments
Matrix assembly assays in vitro
Atomic force microscopy to assess mechanical properties of ECM with and without EPYC
While the literature doesn't explicitly mention contradictions regarding EPYC's function in different cartilage types, they indicate differential expression between cartilage subtypes.
Methodological approach to resolve contradictions:
Comparative studies using both tissue types derived from the same iPSC line
Parallel differentiation protocols with specific modulators to direct cells toward articular or growth plate fates
Comprehensive phenotypic and functional analysis:
Histological assessment of matrix organization
Mechanical testing of tissue constructs
Gene expression profiling under various mechanical and biochemical stimuli
EPYC overexpression and knockdown studies in both cartilage subtypes to compare functional outcomes
Implementation of contradiction detection algorithms to identify inconsistent findings in the literature
The literature indicates that EPYC is among the markers that are downregulated during chondrocyte hypertrophy induced by T3 treatment .
Methodological approach:
Establishment of baseline expression profiles:
qRT-PCR or droplet digital PCR for precise quantification
Correlation with established maturation markers
Development of monitoring systems:
Reporter constructs with fluorescent proteins driven by EPYC promoter
High-content imaging platforms for real-time monitoring
Validation strategies:
Correlation of EPYC expression with matrix production and quality
Functional assessment of mechanical properties
Response to differentiation-modulating agents
Expression data table:
Differentiation Stage | EPYC Expression | Other Markers | T3 Treatment Effect |
---|---|---|---|
Early chondrogenesis | High | SOX9+, COL2A1+, ACAN+ | N/A |
Pre-hypertrophic | High | COL2A1+, COL11A1+, MATN1+ | Downregulation |
Hypertrophic | Low | COL10A1+, SP7+, VEGF+ | Further reduction |
Based on research into human sensemaking in complex data environments, similar approaches can be applied to EPYC research .
Methodological approach:
Integration of ethnographic approaches with data science:
Observation of how researchers from different disciplines interpret EPYC data
Interviews with cartilage biologists, geneticists, and clinicians
Development of visual analytics tools specific to EPYC data:
Interactive visualization of expression data across developmental trajectories
Network representations of protein-protein interactions
Collaborative workshops bringing together experts from different fields:
Structured exercises to identify knowledge gaps
Co-development of research priorities
Implementation of machine learning approaches to identify patterns in EPYC data that may not be apparent to human researchers
Recent developments in contradiction detection could be applied to EPYC research, as shown by the CONTRADOC dataset methodology .
Methodological approach:
Application of natural language processing techniques to extract EPYC-related claims from literature
Implementation of contradiction detection algorithms to identify inconsistent findings
Meta-analysis frameworks to resolve contradictions based on:
Experimental methods used
Model systems (human vs. animal, in vitro vs. in vivo)
Temporal tracking of evolving understanding
Development of standardized reporting frameworks specific to cartilage research
Evaluation metrics similar to those used in CONTRADOC (accuracy, precision, recall, F1 scores)
The EPIC (Extended Perception, Interaction & Cognition) Research Group's approach to human-computer interaction could inform better visualization of complex EPYC expression data .
Methodological approach:
Development of holistic visualization systems that combine:
Spatial representation of EPYC expression in developing cartilage
Temporal progression of expression changes
Interactive elements allowing researchers to explore data relationships
Implementation of perception-action couplings in data exploration:
Haptic feedback systems for exploring 3D matrix structures
Augmented reality visualizations of molecular interactions
Design approaches that facilitate:
Break-through simplification of complex EPYC regulatory networks
Enhanced memorability of key expression patterns
Stronger sense of agency in data exploration experiences
Epiphycan, also known as dermatan sulfate proteoglycan 3 (DSPG3), is a member of the small leucine-rich proteoglycan (SLRP) family. This protein plays a significant role in the extracellular matrix, particularly in skeletal tissues such as the growth plate of long bones, articular cartilage, and intervertebral discs . The recombinant form of human epiphycan is produced using advanced biotechnological methods, often involving expression in HEK293 cells .
Epiphycan is composed of a core protein with attached glycosaminoglycan (GAG) chains. The human recombinant form of epiphycan typically consists of a single, glycosylated polypeptide chain containing 309 amino acids, with a molecular mass of approximately 35.5 kDa . The protein is often fused to a His-tag at the C-terminus to facilitate purification .
Epiphycan is involved in various biological processes, primarily related to tissue development, repair, and homeostasis. It interacts with collagen fibrils and other extracellular matrix proteins, regulating fibrillogenesis and influencing cell behavior and tissue organization . The unique structure of epiphycan allows it to bind to growth factors, cytokines, and other matrix proteins, thereby modulating their activity and availability .
The involvement of epiphycan in tissue development and repair has highlighted its potential as a therapeutic target. Research suggests that epiphycan may play a role in bone formation and the establishment of the ordered structure of cartilage through matrix organization . Its ability to interact with various growth factors and cytokines makes it a promising candidate for therapeutic interventions in conditions related to tissue damage and repair .
Human recombinant epiphycan is produced using HEK293 cells, a widely used cell line for recombinant protein expression. The protein is purified using proprietary chromatographic techniques to achieve a purity greater than 95%, as determined by SDS-PAGE . The recombinant protein is typically formulated in a sterile, colorless solution containing glycerol and phosphate-buffered saline (PBS) at pH 7.4 .
For optimal stability, human recombinant epiphycan should be stored at 4°C if used within 2-4 weeks. For longer storage periods, it is recommended to freeze the protein at -20°C, with the addition of a carrier protein such as human serum albumin (HSA) or bovine serum albumin (BSA) to prevent degradation . It is important to avoid multiple freeze-thaw cycles to maintain the protein’s integrity and biological activity .